Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Nucleoside Reverse Transcriptase Inhibitor (NRTIs)
Nucleoside Reverse Transcriptase Inhibitor · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single Arm | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Nucleoside Reverse Transcriptase Inhibitor (NRTIs) | DRUG | in accordance with current clinical HIV treatment guidelines |
| ritonavir | DRUG | 100 mg bid orally, Days 1-14 |
| saquinavir [Invirase] | DRUG | 500 mg bid orally Days 1-7, 1000 mg bid orally Days 8-14 |
Inclusion Criteria: * Adult patients, \>/= 18 years of age * HIV-1 infection * Currently treatment-naïve and eligible to initiate a ritonavir-boosted Protease Inhibitor based regimen and willing and able to initiate saquinavir/ritonavir therapy for the first 14 days; the saquinavir/ritonavir regime...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
Nucleoside Reverse Transcriptase Inhibitor is being studied for the treatment of HIV Infections, an infectious disease indication. It is a small molecule therapeutic developed by Roche Holding AG. The compound is in Phase 1 clinical development, and the completed trial enrolled treatment-naive HIV-1 infected patients.
Nucleoside Reverse Transcriptase Inhibitor is developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is the sponsor behind the clinical program evaluating this small molecule in HIV Infections.
Nucleoside Reverse Transcriptase Inhibitor is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. One Phase 1 trial has been completed, and no trials are currently active.
Nucleoside Reverse Transcriptase Inhibitor has been evaluated in the Phase 1 trial NCT01638650, titled A Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naive HIV-1 Infected Patients. That trial was completed, enrolled 23 participants, used a randomized design, and was conducted in the United Kingdom.
Yes. Nucleoside Reverse Transcriptase Inhibitor is also known as Nucleoside Reverse Transcriptase Inhibitor (NRTIs). The abbreviated form NRTIs refers to the same drug asset developed by Roche Holding AG for HIV Infections.
The completed Phase 1 trial of Nucleoside Reverse Transcriptase Inhibitor, NCT01638650, enrolled 23 participants. It was a randomized study without a control group and was not double blinded. Participants were 18 years of age or older, of all sexes, and were not healthy volunteers.